Amid the broader market slump caused by concerns about the spread of the COVID-19 Delta variant and rising inflation, shares of PepsiCo (NASDAQ:PEP), Novo Nordisk (NYSE:NVO),...
A look at the day ahead from Saikat Chatterjee Markets are awaiting one of this year's most important U.S. data releases-- inflation data for June. A yearly rise of 4.9% is...
Gilead Sciences (NASDAQ:GILD), Inc. GILD announced that the FDA has approved a label expansion of its hepatitis C virus (HCV) drug, Epclusa.The drug has now been approved for...
Pune, India., June 09, 2021 (GLOBE NEWSWIRE) -- Peptide Therapeutics Market: Key InsightsAccording to our new research study on "Peptide Therapeutics Market to 2027 – Global...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | ||||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | ||||
| 1.14 | 1.22 | 1.12 | -0.0900 | -7.32% | 8.00M | ||||
| 206.53 | 206.89 | 203.56 | -7.51 | -3.51% | 25.54M | ||||
| 141.34 | 141.70 | 140.33 | +0.63 | +0.45% | 4.47M | ||||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | ||||
| 150.64 | 152.84 | 150.25 | -0.29 | -0.19% | 9.67M | ||||
| 57.01 | 57.33 | 56.45 | +0.54 | +0.96% | 12.14M | ||||
| 248.25 | 250.56 | 246.68 | -0.03 | -0.01% | 5.88M | ||||
| 17.85 | 17.85 | 17.56 | +0.45 | +2.59% | 6.50K | ||||
| 2,756.30 | 2,776.20 | 2,694.00 | +89.8 | +3.37% | 1.32M | ||||
| 94.55 | 97.17 | 94.19 | -1.02 | -1.07% | 13.22M | ||||
| 95.21 | 100.55 | 90.81 | -13.45 | -12.38% | 15.42M | ||||
| 28.15 | 28.21 | 27.94 | +0.14 | +0.50% | 30.23M | ||||
| 125.97 | 126.32 | 123.92 | +3.34 | +2.72% | 7.93M | NASDAQ |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson’s diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
